Calliditas Therapeutics’ nefecon featured in four posters at nephrology congress

Calliditas Therapeutics announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon delayed-release capsules in patients with IgA nephropathy, presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16. In a sub-analysis of the phase III NefIgArd trial, Nefecon treatment consistently improved the estimated glomerular filtrate rate over the 2-year study period compared to placebo. 72 patients experienced sustained eGFR improvement, which persisted for up to 18 months after treatment initiation, even after the treatment cessation at month 9. Nefecon treatment may support them in reaching the RaDaR treatment target of an eGFR decline pivotal in mitigating the risk of kidney failure in their lifetime. In the 2-year NefIgArd Phase 3 trial, during the 9-month treatment period, Nefecon showed a 30% reduction in UPCR compared to the placebo, sustained for 2 years. The treatment effect of Nefecon on the risk of kidney function decline was consistent regardless of baseline UPCR. These findings strongly suggest preserved kidney function and provide support for Nefecon as a disease-modifying therapy in patients with IgAN. A 2-year analysis of results of quality of life revealed no meaningful differences in any QoL domain between Nefecon and placebo groups after 9 months of treatment. Responses to Nefecon treatment from the full 2-year NefIgArd trial were assessed in patients identifying as Asian or White. Regardless of race and ethnicity, Nefecon showed a favorable change in eGFR compared to placebo. Nefecon also demonstrated greater reductions in UPCR at 9 and 24 months with notable delays in kidney function decline events. These effects were consistent across races and ethnicities. These findings highlight Nefecon’s efficacy and tolerability across different racial and ethnic groups.